Alfred Garfall: Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma

Alfred Garfall, MD, discusses updated safety and efficacy data from a phase I trial evaluating teclistamab, a bispecific BCMA x CD3 antibody, for the treatment of patients with relapsed and/or refractory multiple myeloma.